---
document_datetime: 2025-05-15 12:43:49
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/filsuvez-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: filsuvez-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.2181864
conversion_datetime: 2025-12-30 01:21:16.176108
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Filsuvez

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, please also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                        | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                        |
|----------------------|----------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|------------------------------------------------|
| Variation type IB /  | C.I.11 Introduction of, or change(s) to, the | 15/05/2025                          |                                             |                                  | To provide a revised RMP version following the |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000249374   | obligations and conditions of a marketing authorisation, including the risk management plan - C.I.11.z Other RMP changes (e.g. agreed wording + template change) - Accepted C.I.11.z (IB) - To provide a revised RMP version following the withdrawal of the marketing authorisation for Episalvan (birch bark extract), as recommended within procedure EMEA/H/C/PSUSA/00010446/202207. Furthermore, the final report milestone for the study \"Filsuvez Observational Safety Registry Based Study (FOSteR)\" has been updated to 2032, along with other recommendations received following the post-authorisation measure MEA 001.   | withdrawal of the marketing authorisation for Episalvan (birch bark extract). Furthermore, the final report milestone for the study \"Filsuvez Observational Safety Registry Based Study (FOSteR)\" has been updated to 2032, along with other recommendations received following the post- authorisation measure MEA 001.   |
|---------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|